secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-118338
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Q3 revenue up 42% to $7.3M; guides for 50%+ growth and positive EBITDA in 2025
--------------------------------------------------------------------------------

- Q3 revenue $7.3M (+42% YoY); nine-month revenue $21.2M (+66% YoY). Gross margin 86%.
- Operating loss improved to $8.7M (Q3) and $28.6M (9M) from $18.6M and $40.2M in 2023.
- Net loss per share $0.12 (Q3) vs $0.14; cash $11.3M plus $25M OrbiMed facility.
- 2025 guidance: >50% revenue growth, >20% opex reduction, positive full-year EBITDA, H2 cash flow positive.
- Launched TriNav LV system and TriGuide catheter; initiated PROTECT trial for thyroid embolization ($400M market).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924118338/0001104659-24-118338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924118338/tm2428379d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-118338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer